Last reviewed · How we verify

Clarithromycin placebo tablets

TenNor Therapeutics (Suzhou) Limited · Phase 3 active Small molecule

Clarithromycin placebo tablets is a Small molecule drug developed by TenNor Therapeutics (Suzhou) Limited. It is currently in Phase 3 development for Control arm in phase 3 clinical trial (active indication unknown). Also known as: Clarithromycin placebo, Clarithromycin, ABT-268, Biaxin.

This is a placebo tablet with no active pharmacological mechanism.

This is a placebo tablet with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trial (active indication unknown).

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameClarithromycin placebo tablets
Also known asClarithromycin placebo, Clarithromycin, ABT-268, Biaxin, clarithromycin
SponsorTenNor Therapeutics (Suzhou) Limited
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Clarithromycin placebo tablets contain no active drug substance and are used as a control comparator in clinical trials. They are designed to be indistinguishable from active clarithromycin tablets to maintain blinding in phase 3 studies, allowing researchers to isolate the true therapeutic effect of the active drug from placebo response.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Clarithromycin placebo tablets

What is Clarithromycin placebo tablets?

Clarithromycin placebo tablets is a Small molecule drug developed by TenNor Therapeutics (Suzhou) Limited, indicated for Control arm in phase 3 clinical trial (active indication unknown).

How does Clarithromycin placebo tablets work?

This is a placebo tablet with no active pharmacological mechanism.

What is Clarithromycin placebo tablets used for?

Clarithromycin placebo tablets is indicated for Control arm in phase 3 clinical trial (active indication unknown).

Who makes Clarithromycin placebo tablets?

Clarithromycin placebo tablets is developed by TenNor Therapeutics (Suzhou) Limited (see full TenNor Therapeutics (Suzhou) Limited pipeline at /company/tennor-therapeutics-suzhou-limited).

Is Clarithromycin placebo tablets also known as anything else?

Clarithromycin placebo tablets is also known as Clarithromycin placebo, Clarithromycin, ABT-268, Biaxin, clarithromycin.

What development phase is Clarithromycin placebo tablets in?

Clarithromycin placebo tablets is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing